Related references
Note: Only part of the references are listed.Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries
Swathi Pathadka et al.
DRUGS (2022)
Nanoparticles in the clinic: An update
Aaron C. Anselmo et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2019)
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
Anne-Gaelle Dosne et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States
Ahmad Y. Abuhelwa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring
Jodi M. Lestner et al.
CLINICAL INFECTIOUS DISEASES (2009)
Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever
D. -G. Lee et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation
J. W. Mouton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts
F. Sabatelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
A Glasmacher et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients
Stefanie Hennig et al.
CLINICAL PHARMACOKINETICS (2006)
Population pharmacokinetics of itraconazole in Thai HIV-1-Infected persons
CHW Koks et al.
THERAPEUTIC DRUG MONITORING (2003)
Nanosizing: a formulation approach for poorly-water-soluble compounds
E Merisko-Liversidge et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Share Paper
